DPP4 Inhibitors in the Management of Hospitalized Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Introduction We studied the effects of dipeptidyl peptidase 4 (DPP4) inhibitors on glycemic control in non-critically ill patients admitted to hospital. Methods We searched MEDLINE and EMBASE for published studies in English up to July 2019. We included randomized clinical trials (RCTs) that compared DPP4 inhibitors plus insulin supplementation versus basal-bolus insulin regimen in the management of hyperglycemia non-critically ill patients with type 2 diabetes admitted to hospital. Mean difference (MD), relative risk (RR), and 95% confidence intervals (CI) were generated to interpret the data. Results Of 401 papers, four RCTs including 648 participants met inclusion criteria. There was no significant difference in mean daily blood glucose level between the two groups (MD 4.63; 95% CI = - 1.57, 10.83; p = 0.14) (I 2 = 14%, p = 0.32). Total insulin dose per day was lower in patients receiving DPP4 inhibitors (MD - 14.27; CI = - 22.47, - 6.07; p = 0.001) (I 2 = 92%, p = 0.001). Also, the number of insulin injection was significantly lower in patients receiving DPP4 inhibitors (MD - 0.79; CI = - 1.01, - 0.57; p = 0.001) (I 2 = 0%, p = 0.68). The rate of hypoglycemia was not significantly different between the two groups (RR 0.60, CI = 0.34, 1.074; p = 0.08) (I 2 = 37.3%, p = 0.18). Treatment failure was not significantly different between the two groups (RR 0.87, CI = 0.64, 4.8; p = 0.38) (I 2 = 49%, p = 0.11). Conclusion The results indicate that using DPP4 inhibitors plus basa…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For noncritically ill persons with T2D and mild-to-moderate hyperglycemia (ie, admission glycemia below 180 to 200 mg/dL),1266 the use of basal insulin plus correctional insulin (basal-plus regimen),108 or basal insulin with DPP-4 inhibitors, or DPP-4 inhibitors plus correctional insulin doses with rapid-acting insulin may provide equal glycemic control to basal-bolus insulin.1350–1352”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1350]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The well-built clinical question: A key to evidence-based decisions
(1995) · ACP Journal Club · doi:10.7326/acpjc-1995-123-3-a12 · Cited by 2,931
Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes
Umpierrez, G. E., Isaacs, S. D., Bazargan, N., You, X., Thaler, L. M., & Kitabchi, A. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8341 · Cited by 2,195
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Glucose Control and Mortality in Critically Ill Patients
Finney, S. J. (2003) · JAMA · doi:10.1001/jama.290.15.2041 · Cited by 1,055
Umpierrez, G. E., Smiley, D., Jacobs, S., Peng, L., Temponi, A., Mulligan, P., Umpierrez, D., Newton, C., Olson, D., & Rizzo, M. (2011) · Diabetes Care · doi:10.2337/dc10-1407 · Cited by 720
Early Postoperative Glucose Control Predicts Nosocomial Infection Rate in Diabetic Patients
Pomposelli, J. J., Baxter, J. K., Babineau, T. J., Pomfret, E. A., Driscoll, D. F., Forse, R. A., & Bistrian, B. R. (1998) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/014860719802200277 · Cited by 700
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Vargas‐Alarcón, G., González-Salazar, M. D. C., Vázquez-Vázquez, C., Hernández-Díazcouder, A., Sánchez‐Muñoz, F., Reyes-Barrera, J., Críales-Vera, S., Sánchez-Guerra, M., Osorio-Yáñez, C., & Posadas‐Sánchez, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.592646 · Cited by 10
Morones-Gamboa, J. C., Pérez, M., Muñoz‐Ortega, M. H., Sánchez, E., Ávila‐Blanco, M. E., Topete-Reyes, J. F., Ventura‐Juárez, J., & Martínez-Hernández, S. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111372 · Cited by 7
“Linagliptin is primarily used in the treatment of type 2 DM [38,39], although studies also indicate its use in atherosclerosis, dyslipidemias, and hypertension [40].”
BackgroundGenestreti, P., Furtado, R. H. D. M., Salsoso, R., Dalçóquio, T. F., Franci, A., Menezes, F. R., Caporrino, C. A., Ferrari, A., Nakashima, C. A. K., Filho, M. S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195776 · Cited by 8
Marino, E. C., Momesso, D., Toyoshima, M. T. K., de Almeida, M. F. O., Schaan, B. D., Negretto, L. A. F., Junior, A. C. S., Cukier, P., Genestreti, P., Feitosa, A. C. R., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01585-z · Cited by 10
Metadata
- Authors
- Rabizadeh, S., Tavakoli Ardakani, M. A., Mouodi, M., Bitaraf, M., Shab-Bidar, S., Esteghamati, A., & Nakhjavani, M.
- Affiliations
- Endocrine and Metabolism Research Center (IR)
- Corresponding author
- Nakhjavani, Manouchehr
- Venue
- Advances in Therapy
- Published
- 2020-07-15
- Volume
- 37
- Issue
- 9
- Pages
- 3660-3675
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W3042913079
- Cited by
- 8
- References
- 31
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 1
- FWCI
- 0.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Advances in Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- DPP-4 inhibitors, type 2 diabetes, hospitalized patients, glycemic control, multiple daily insulin injections, insulin dose reduction, hypoglycemia, hyperglycemia, insulin injection frequency, treatment failure, non-critically ill patients, non-inferiority, blood glucose variability, insulin sensitivity, insulin secretion, insulin sensitivity index, insulin resistance index
- MeSH terms
- Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Inpatients, Insulin, Male, Middle Aged, Randomized Controlled Trials as Topic, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DPP4 Inhibitors in the Management of Hospitalized Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. https://app.cochat.ai/papers/10.1007/s12325-020-01434-7
- The paper
- Rabizadeh, S., Tavakoli Ardakani, M. A., Mouodi, M., Bitaraf, M., Shab-Bidar, S., Esteghamati, A., & Nakhjavani, M. (2020). DPP4 Inhibitors in the Management of Hospitalized Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Advances in Therapy. https://doi.org/10.1007/s12325-020-01434-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.